Clinical Cancer Research, Vol 3, Issue 2 221-226, Copyright © 1997 by American Association for Cancer Research

ARTICLES

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients

C Scheibenbogen, KH Lee, S Mayer, S Stevanovic, U Moebius, W Herr, HG Rammensee and U Keilholz
Department of Hematology/Oncology, Medizinische Klinik V, University of Heidelberg, 69115 Heidelberg, Germany.

An enzyme-linked immunospot (ELISPOT) assay was adapted to detect peptide-specific CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMCs). In HLA-A1-, HLA-A2-, and/or HLA-A3-positive individuals, we determined the release of IFN-gamma on a single cell level in response to three different peptide epitopes derived from the influenza matrix protein and nuclear protein containing the HLA-A2.1- and HLA-A1- or HLA-A3-binding motif, respectively. Comparison of the ELISPOT assay with the standard chromium release assay revealed a close correlation between the number of peptide-specific IFN-gamma-releasing T cells in PBMCs and the level of specific cytotoxicity after 14 days of in vitro expansion. The ELISPOT assay detected T cells with specificity for the HLA-A2. 1-binding epitope derived from the matrix protein in 76% of HLA-A2-positive healthy individuals (n = 25); the median frequency was 41 in 10(6) PBMCs. We also detected peptide-specific T cells in 10 of 12 HLA-A2-positive patients with metastatic melanoma with a median frequency of 20.5 in 10(6) PBMCs. In 10 of 24 HLA-A3-positive individuals and in 2 of 14 HLA-A1-positive individuals, peptide-specific T cells for a HLA-A3- and a HLA-A1-binding epitope derived from the nucleoprotein, respectively, were present. In conclusion, the ELISPOT assay may be suitable to monitor a peptide-specific T-cell response in vaccination protocols using peptides derived from tumor or viral antigens.

This article has been cited by other articles:

				E. Assarsson, H.-H. Bui, J. Sidney, Q. Zhang, J. Glenn, C. Oseroff, I. N. Mbawuike, J. Alexander, M. J. Newman, H. Grey, et al. Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans J. Virol., December 15, 2008; 82(24): 12241 - 12251. [Abstract] [Full Text] [PDF]

				K. H. Kim, W. Greenfield, E. Shotts, and M. Nakagawa Detection of Human Papillomavirus Type 16-Specific T Lymphocytes by a Recombinant Vaccinia Virus-Based Enzyme-Linked Immunospot Assay Clin. Vaccine Immunol., April 1, 2007; 14(4): 362 - 368. [Abstract] [Full Text] [PDF]

				W. Wang, J. Epler, L. G. Salazar, and S. R. Riddell Recognition of Breast Cancer Cells by CD8+ Cytotoxic T-Cell Clones Specific for NY-BR-1. Cancer Res., July 1, 2006; 66(13): 6826 - 6833. [Abstract] [Full Text] [PDF]

				B. Comin-Anduix, A. Gualberto, J. A. Glaspy, E. Seja, M. Ontiveros, D. L. Reardon, R. Renteria, B. Englahner, J. S. Economou, J. Gomez-Navarro, et al. Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays Clin. Cancer Res., January 1, 2006; 12(1): 107 - 116. [Abstract] [Full Text] [PDF]

				S. M. Goldberg, S. M. Bartido, J. P. Gardner, J. A. Guevara-Patino, S. C. Montgomery, M.-A. Perales, M. F. Maughan, J. Dempsey, G. P. Donovan, W. C. Olson, et al. Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles Clin. Cancer Res., November 15, 2005; 11(22): 8114 - 8121. [Abstract] [Full Text] [PDF]

				P. Q. Hu, R. J. Tuma-Warrino, M. A. Bryan, K. G. Mitchell, D. E. Higgins, S. C. Watkins, and R. D. Salter Escherichia coli Expressing Recombinant Antigen and Listeriolysin O Stimulate Class I-Restricted CD8+ T Cells following Uptake by Human APC J. Immunol., February 1, 2004; 172(3): 1595 - 1601. [Abstract] [Full Text] [PDF]

				D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz Natural T Cell Immunity against Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303. [Abstract] [Full Text] [PDF]

				A. Admon, E. Barnea, and T. Ziv Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides Mol. Cell. Proteomics, June 1, 2003; 2(6): 388 - 398. [Abstract] [Full Text] [PDF]

				F. Buseyne, D. Scott-Algara, F. Porrot, B. Corre, N. Bellal, M. Burgard, C. Rouzioux, S. Blanche, and Y. Riviere Frequencies of Ex Vivo-Activated Human Immunodeficiency Virus Type 1-Specific Gamma-Interferon-Producing CD8+ T Cells in Infected Children Correlate Positively with Plasma Viral Load J. Virol., November 13, 2002; 76(24): 12414 - 12422. [Abstract] [Full Text] [PDF]

				C. Scheibenbogen, A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen, and U. Keilholz CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood, August 28, 2002; 100(6): 2132 - 2137. [Abstract] [Full Text] [PDF]

				K.-J. Malmberg, V. Arulampalam, F. Ichihara, M. Petersson, K. Seki, T. Andersson, R. Lenkei, G. Masucci, S. Pettersson, and R. Kiessling Inhibition of Activated/Memory (CD45RO+) T Cells by Oxidative Stress Associated with Block of NF-{kappa}B Activation J. Immunol., September 1, 2001; 167(5): 2595 - 2601. [Abstract] [Full Text] [PDF]

				M. H. Andersen, L. O. Pedersen, B. Capeller, E.-B. Brocker, J. C. Becker, and P. thor Straten Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients Cancer Res., August 1, 2001; 61(16): 5964 - 5968. [Abstract] [Full Text] [PDF]

				M. von Mehren, P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, S. McLaughlin, M. T. Beard, et al. The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1181 - 1191. [Abstract] [Full Text]

				J. L. Marshall, R. J. Hoyer, M. A. Toomey, K. Faraguna, P. Chang, E. Richmond, J. E. Pedicano, E. Gehan, R. A. Peck, P. Arlen, et al. Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses J. Clin. Oncol., December 1, 2000; 18(23): 3964 - 3973. [Abstract] [Full Text] [PDF]

				M. V. Dhodapkar, J. W. Young, P. B. Chapman, W. I. Cox, J. F. Fonteneau, S. Amigorena, A. N. Houghton, R. M. Steinman, and N. Bhardwaj Paucity of Functional T-Cell Memory to Melanoma Antigens in Healthy Donors and Melanoma Patients Clin. Cancer Res., December 1, 2000; 6(12): 4831 - 4838. [Abstract] [Full Text]

				D. Nagorsen, U. Keilholz, L. Rivoltini, A. Schmittel, A. Letsch, A. M. Asemissen, G. Berger, H.-J. Buhr, E. Thiel, and C. Scheibenbogen Natural T-cell Response against MHC Class I Epitopes of Epithelial Cell Adhesion Molecule, her-2/neu, and Carcinoembryonic Antigen in Patients with Colorectal Cancer Cancer Res., September 1, 2000; 60(17): 4850 - 4854. [Abstract] [Full Text]

				M. von Mehren, P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L. M. Weiner Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas Clin. Cancer Res., June 1, 2000; 6(6): 2219 - 2228. [Abstract] [Full Text]

				T. L. Whiteside Monitoring of Antigen-Specific Cytolytic T Lymphocytes in Cancer Patients Receiving Immunotherapy Clin. Vaccine Immunol., May 1, 2000; 7(3): 327 - 332. [Full Text] [PDF]

				J. P. Eder, P. W. Kantoff, K. Roper, G. Xu, G. J. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. K. Oh, P. Arlen, et al. A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1632 - 1638. [Abstract] [Full Text]

				T. Asai, W. J. Storkus, and T. L. Whiteside Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines Clin. Vaccine Immunol., March 1, 2000; 7(2): 145 - 154. [Abstract] [Full Text] [PDF]

				X.-L. Huang, Z. Fan, C. Kalinyak, J. W. Mellors, and C. R. Rinaldo Jr. CD8+ T-Cell Gamma Interferon Production Specific for Human Immunodeficiency Virus Type 1 (HIV-1) in HIV-1-Infected Subjects Clin. Vaccine Immunol., March 1, 2000; 7(2): 279 - 287. [Abstract] [Full Text] [PDF]

				C. Pique, A. Ureta-Vidal, A. Gessain, B. Chancerel, O. Gout, R. Tamouza, F. Agis, and M.-C. Dokhelar Evidence for the Chronic In Vivo Production of Human T Cell Leukemia Virus Type I Rof and Tof Proteins from Cytotoxic T Lymphocytes Directed against Viral Peptides J. Exp. Med., February 7, 2000; 191(3): 567 - 572. [Abstract] [Full Text] [PDF]

				E. Loing, M. Andrieu, K. Thiam, D. Schorner, K.-H. Wiesmuller, A. Hosmalin, G. Jung, and H. Gras-Masse Extension of HLA-A*0201-Restricted Minimal Epitope by N{epsilon}-Palmitoyl-lysine Increases the Life Span of Functional Presentation to Cytotoxic T Cells J. Immunol., January 15, 2000; 164(2): 900 - 907. [Abstract] [Full Text] [PDF]

				A. Anichini, A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A. M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, et al. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CTL)-defined, Melanocyte-specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-specific CTLs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions J. Exp. Med., September 6, 1999; 190(5): 651 - 668. [Abstract] [Full Text] [PDF]